{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:21:43Z","timestamp":1793362903691,"version":"4.5.0"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1313,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Aims<\/jats:italic>\n          <\/jats:bold>\u2007Preliminary results indicate higher absorption of triclabendazole (TCBZ) administered postprandially. Therefore, the influence of food on the pharmacokinetics of TCBZ and its active sulphoxide (TCBZ\u2010SO) and sulphone (TCBZ\u2010SO2) metabolites was investigated.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold>\u2007Two single doses (10\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>\u200a) of TCBZ were administered to 20 patients with fascioliasis. Ten patients were first given the drug after a high energy breakfast and then, 48\u2003h later, after an overnight fast. The other 10 patients first received the drug in fasting state and then, 48\u2003h later, after breakfast. A low energy breakfast was served 2\u2003h after drug administration for fasting state.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold>\u2007Compared with the fasting state, an increased AUC and <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> after food intake (significant, <jats:italic>P<\/jats:italic>&lt;0.0001) was shown from the values of TCBZ, TCBZ\u2010SO and TCBZ\u2010SO2. The mean AUC for TCBZ (fasting: 1.55, fed: 5.72\u2003\u03bcmol\u2003l<jats:sup>\u22121<\/jats:sup> h), TCBZ\u2010SO (fasting: 177, fed: 386\u2003\u03bcmol\u2003l<jats:sup>\u22121<\/jats:sup> h) and TCBZ\u2010SO2 (fasting: 13.9, fed: 30.5\u2003\u03bcmol\u2003l<jats:sup>\u22121<\/jats:sup> h) indicated a large availability increase with food and the strong systemic predominance of the active sulphoxide metabolite over the unchanged drug. (All patients were cured at the end of the trial except one who required a second course of two postprandial doses of triclabendazole (10\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> each). Tolerability to the treatment among the patients was good.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold>\u2007The administration of triclabendazole with food is recommended for improved systemic availability in patients with fascioliasis or paragonimiasis.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1998.00725.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:30:50Z","timestamp":1047357050000},"page":"601-604","source":"Crossref","is-referenced-by-count":53,"title":["Effect of food on the bioavailability of triclabendazole in patients with fascioliasis"],"prefix":"10.1111","volume":"45","author":[{"given":"J. B.","family":"Lecaillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Godbillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Campestrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Naquira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Poltera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4894(87)90077-4"},{"key":"e_1_2_5_3_2","first-page":"227","article-title":"Triclabendazole.","volume":"21","author":"Robinson CP","year":"1985","journal-title":"Drugs Today"},{"key":"e_1_2_5_4_2","first-page":"38","article-title":"Progress in assessment of the morbidity due to Fasciola hepatica infection: A review of the recent literature.","volume":"87","author":"Chen MG","year":"1990","journal-title":"Trop Dis Bull"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","unstructured":"LoutanL BouvierM RojanawisutB et al.Single treatment of invasive Fascioliasis with triclabendazole.Lancet1989;8659:383","DOI":"10.1016\/S0140-6736(89)90557-6"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(92)90247-A"},{"key":"e_1_2_5_7_2","first-page":"44","article-title":"Eficacia del triclabendazole en Paragonimiasis pulmonar humana refractaria a la emetina, bithionol y praziquantel.","volume":"17","author":"Calvopi\u00f1a M","year":"1993","journal-title":"Parasitolog\u00eda al Dia"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80474-5"},{"key":"e_1_2_5_9_2","unstructured":"BoltonSPharmaceutical statistics 2nd (ed.) New York: Marcel Dekker 1990; chapter11"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1987.tb00078.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.20.040180.001133"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00540964"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061694"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03825.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00725.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00725.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2125.1998.00725.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00725.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:54:10Z","timestamp":1694404450000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1998.00725.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1365-2125.1998.00725.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00725.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}